Pennsylvania Psilocybin Research Bill Faces A Major Obstacle In House Committee

A Pennsylvania legislation poised to promote research into the therapeutic potential of psilocybin mushrooms for certain mental health conditions is facing some challenges as a key House committee continues to express reservations even though the bill was previously amended, reported Marijuana Moment.

Sponsored by Rep. Tracy Pennycuick (R) and titled the “Psilocybin Data Act,” the bill was initially introduced last year. However, the measure did not advance. 

A revised version, which removes a provision allowing the state Department of Health to approve two entities to cultivate the psychedelic for research purposes, was filed earlier this month.

However, Pennycuick told Marijuana Moment that the “watered-down version” of the legislation is still facing some opposition in the House Health Committee, where it’s been referred.

Pennycuick said that he is “not sure” that the chair of the committee, Rep. Kathy Rapp (R), “will even run this.”

“To say I am frustrated is mild compared to how I really feel," the sponsor said. "I have worked this bill for months.”

She added that despite her efforts to build support for the legislation, the chairwoman “shifted course due to an overdose death in her district,” allegedly involving so-called “magic mushrooms.”

“I don’t understand it,” Pennycuick, an Army veteran of 26 years who assembled a cadre of 20 cosponsors, said. “It is frustrating.”

Pennycuick’s newly revised bill, HB 2421, says that  Commonwealth is “in desperate need of innovative and cost-effective mental health treatment to combat this significant public health crisis,” citing statistics about increased rates of mental health complications.   

The proposed legislation looks to create a framework for clinical studies of psilocybin, the active psychedelic compound in magic mushrooms, which is proving effective at treating a range of ailments from depression to PTSD to drug dependency.

Photo: Courtesy of Nathan Karsgaard on Unsplash

Posted In: HouseKathy RappMarijuana MomentPsilocybinCannabisNewsPsychedelicsPoliticsMarketsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.